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Epstein-Barr virus requires glycoproteins gH/gL, gB,
and gp42 to fuse its lipid envelope with B cells.
Gp42 is a type II membrane protein consisting of
a flexible N-terminal region, which binds gH/gL, and
a C-terminal lectin-like domain that binds to the
B-cell entry receptor human leukocyte antigen (HLA)
class II. Gp42 triggers membrane fusion after HLA
binding, a process that requires simultaneousbinding
to gH/gL and a functional hydrophobic pocket in the
lectin domain adjacent to the HLA binding site. Here
we present the structure of gp42 in its unbound
form. Comparisons to the previously determined
structure of a gp42:HLA complex reveals additional
N-terminal residues forming part of the gH/gL binding
site and structural changes in the receptor binding
domain. Although the core of the lectin domain
remains similar, significant shifts in two loops and
anahelix bordering theessential hydrophobic pocket
suggest a structural mechanism for triggering fusion.
INTRODUCTION
Epstein-Barr virus (EBV) is a member of the g-herpesvirus family,
which also includes Kaposi’s sarcoma-associated herpesvirus.
The first exposure to EBV in adolescence or adulthood can result
in acute infectious mononucleosis. EBV is an oncogenic virus
strongly associated with a number of B cell and epithelial cell
cancers, including Burkitt’s lymphoma and nasopharyngeal
carcinoma. Immunosuppressed individuals can develop EBV-
related illnesses, such as lymphoproliferative disorders, oral
hairy leukoplakia, and others (Rickinson and Kieff, 2007).
EBV is an enveloped virus that uses multiple viral glycopro-
teins to engage cellular receptors and infect epithelial and
B cells. EBV-mediated entry into B cells requires four viral glyco-
proteins, gp42, gB, and the gH/gL heterodimeric complex, but
entry into epithelial cells only requires gB and gH/gL (Haan
et al., 2001; Li et al., 1995). These latter three proteins are
conserved across the herpesvirus family. Although cellular
receptors for EBV gB and gH/gL have not been identified,
studies have shown that gB and gH/gL are essential for efficientStructure 17, 223membrane fusion (McShane and Longnecker, 2004; Omerovic
et al., 2005).
EBV gp42 is a type II membrane protein with a transmembrane
domain spanning residues 9–29, and its carboxy terminus on the
external side of the membrane. There is also a cleavage site
adjacent to the transmembrane domain that is responsible for
the in vivo generation of a native soluble form of gp42 (Ressing
et al., 2005). Gp42 is unique to EBV, but there are sequence
homologs among the closely related primate lymphocryptovi-
ruses and functional homologs in other herpesviruses, such as
gD in herpes simplex virus (HSV). EBV gp42 binds cellular HLA
class II proteins that have a critical glutamic acid at human leuko-
cyte antigen (HLA) b chain residue 46, which include all HLA-DR
and -DP proteins as well as most -DQ forms (McShane et al.,
2003). Binding of gp42 to HLA is the trigger for B cell membrane
fusion, and triggering can be observed with soluble forms of
gp42 added exogenously in cell:cell fusion assays and in EBV
infection assays, in which endogenously expressed gp42 is lack-
ing (Kirschner et al., 2006; Wang and Hutt-Fletcher, 1998). Inter-
estingly, gp42 appears to act as a tropism switch that directs
fusion with B cells and inhibits fusion with epithelial cells,
a process mediated through its interactions with gH/gL (Borza
and Hutt-Fletcher, 2002). EBV virions synthesized in B cells
contain a lower amount of gp42 due to sequestration by cellular
HLA class II protein, whereas EBV made in epithelial cells has
a higher amount of gp42 (Borza and Hutt-Fletcher, 2002).
Thus, the life cycle and cellular targeting of EBV is greatly influ-
enced by modulating the incorporation of gp42 into the virus.
The gp42:HLA complex structure was determined previously
and showed the gp42 C-terminal C-type lectin domain (CTLD;
residues 94–221) and part of its N-terminal region (residues
86–94), which formed an extended crystal packing interaction
(Mullen et al., 2002). The N-terminal region was only visible in
the crystal structure beginning with residue 86, with the remain-
ing gp42 residues 33–85 disordered in the lattice. Crystallo-
graphic dimerization of adjacent gp42 molecules was mediated
by this region, with residues 86–95 forming a symmetric antipar-
allel two-stranded b sheet. In this dimer, residue F88 of one gp42
molecule docks into a shallow hydrophobic pocket on the adja-
cent CTLD surface. However, dimerization of gp42 does not
occur with high affinity in solution, as purified soluble gp42 is
monomeric when analyzed by gel-filtration chromatography
(Kirschner et al., 2006). The oligomeric state of gp42 on the viral
membrane has not been established.–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 223
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Structure of EBV Gp42Within the gp42 N-terminal region, residues 47–61 and 67–81
contain key interaction sites for binding gH/gL with high affinity
(Kirschner et al., 2007). A peptide derived from gp42 spanning
residues 36–81 binds to gH/gL with nanomolar affinity similar
to the full-length soluble protein. With epithelial cells, both
soluble gp42 and the 36–81 peptide inhibit membrane fusion
and EBV infection at low nanomolar concentrations (Kirschner
et al., 2007). However, with B cells, the peptide inhibits
membrane fusion by competing with gp42 binding to gH/gL,
whereas the soluble gp42 ectodomain activates fusion (Kirsch-
ner et al., 2007). In order to activate membrane fusion, there is
a dual requirement for the gp42 CTLD to bind HLA class II
receptor while the N terminus of the same gp42 molecule is
bound to gH/gL. An extended hydrophobic pocket on the
surface of gp42 also plays an important role in B cell membrane
fusion, because gp42 mutants in the hydrophobic pocket effec-
tively block membrane fusion but not receptor binding (Silva
et al., 2004). These hydrophobic pocket mutations decouple
Table 1. Crystallographic Data and Model Refinement
Data Collection Statistics
Space group P212121
Resolution (A˚) 30–2.40
Number of unique reflections (total) 14,237 (96,863)
Completeness (%) (last shell) 99.4 (99.1)
Redundancy (last shell) 3.7 (3.5)
Rmerge (%) (last shell)
a 12 (55.4)
< I/sI > (last shell) 14.5 (4.4)
Refinement Statistics
Cell dimensions (a, b, c, a = b = g) 64.79, 67.43, 79.46, 90
Number of reflections in refinement (free) 13,514 (621)
Molecules per asymmetric unit 2
Phaser MR Z score (LL-gain) 17.95 (90)
After initial rigid-body refinement
R value (Rfree), figure of merit
0.454 (0.445), 0.497
After initial restrained refinement
R value (Rfree), FOM
0.286 (0.360), 0.654
Final R factor (%)b 21.6
Final free R factor (%)b 24.2
Number of protein atoms 2,318
Number of water molecules 281
Solvent (%) 46.74
Number of ligand atoms 0
Rmsd bonds (A˚) 0.026
Rmsd angles () 1.7
Average protein B factor (A˚2) 37.9
Ramachandran statistics
Most favored (%) 92.8
Additionally allowed (%) 7.2
Generously allowed (%) 0.0
Disallowed (%) 0.0
a Rmerge =SjIi < I >j/SjIj, where Ii is the intensity of an individual reflection
and < I > is the average intensity of that reflection.
b R factor = SjFoj  jFcj/SjFoj, where Fc is the calculated and Fo is the
observed structure factor amplitude.224 Structure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd Althe linkage between HLA binding and subsequent fusion activa-
tion, suggesting that the pocket plays an important functional
role downstream of receptor binding.
The process of herpesvirus membrane fusion remains incom-
pletely understood, despite recent advances in understanding
gB, HSV-1 gD, and gp42 structures and functions (Heldwein
et al., 2006; Kirschner et al., 2007; Krummenacher et al., 2005;
Lazear et al., 2008; Mullen et al., 2002). The structure of gH/gL
remains to be determined, and the role of gH/gL in the herpes-
virus membrane fusion mechanism remains to be fully clarified.
The dual roles of EBV gp42 as a receptor-dependent activator
of EBV entry into B cells and as an inhibitor of EBV entry into
epithelial cells are so far unique within the herpesvirus family.
Understanding how gp42 mediates these two functions should
help dissect the cascade of events that couple receptor binding
to EBV membrane fusion and entry.
Here we present the structure of gp42 in its unbound form. The
N-terminal gp42 residues closest to the CTLD project outward
at a different angle than in the receptor-bound gp42 structure,
eliminating the dimerization observed previously in the HLA
complex but forming new contacts with the HLA binding sites
of neighboring molecules. Additional N-terminal residues of
gp42 involved in binding gH/gL are observed in the new gp42
structure, as these extended chains make contacts with
symmetry-related gp42 molecules throughout the crystal lattice.
Amino acid residues in both the gp42 hydrophobic pocket and
the HLA binding site are involved in crystal lattice contacts and
remaining protein-protein interaction sites, suggesting possible
roles in the viral entry process. Conformational differences in
the gp42 CTLD hydrophobic pocket are observed when
compared to the receptor-bound form. Two loops and an a helix
shift positions in the hydrophobic pocket, with localized changes
appearing to propagate from one edge of the HLA binding site,
suggesting that these residues may be of functional importance
in activating membrane fusion. These structural differences
provide a model for understanding how gp42 functions as a fusion
activator while binding gH/gL and HLA class II receptor.
RESULTS AND DISCUSSION
Description of the Gp42 Structure
The gp42 crystallization and structure determination is fully
described in Experimental Procedures, and the data and refine-
ment statistics are collected in Table 1. Two gp42 molecules are
present in the crystallographic asymmetric unit, forming comple-
mentary interactions through the hydrophobic pockets of the
C-terminal C-type lectin domains that bury 792 A˚2 of surface
area of each pocket (CTLD, Figure 1). Overall, the two copies
of the gp42 molecule in the asymmetric unit (referred to as model
A and model B) are quite similar (Figure 1). Gp42 model A resi-
dues 76–222 could be built, whereas for model B seven fewer
residues were observed at the N terminus (residues 83–222).
The major differences in the two structures occur in these
N-terminal residues and in one of the CTLD loops. The most
similar parts of the two gp42 structures are residues 95–222,
which form the CTLD and the immediately proximal N-terminal
region (residues 87–94). The overall root-mean-square deviation
(rmsd) after superposition of residues 87–222 of the two gp42
copies is 1 A˚. At residue 86, the main-chain paths of the twol rights reserved
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Structure of EBV Gp42Figure 1. Two Gp42 Molecules in the Asymmetric Unit
Ribbon diagrams of the two gp42 molecules in the asymmetric unit in side (A) and top (B) views, colored from blue to red starting at the N terminus. The N and
C termini of each chain are marked. Molecule B has a longer N terminus (starting at residue 76) than molecule A (starting at residue 82). Both N termini form
extended regions heading away from the C-terminal C-type lectin domain (CTLD). The broad hydrophobic pockets are indicated in (B).molecules deviate significantly due to crystal packing interac-
tions.
The Gp42 N-Terminal Region
The N-terminal region of gp42 is an approximately 60 residue
long, flexible, extended chain protruding away from the CTLD.
The N-terminal residues observed in the crystal structures
appear to be largely dependent on lattice interactions in both
the free and HLA-bound gp42 structures (Figures 1 and 2),
consistent with the observation that a synthetic peptide from
this region binds to gH/gL similarly to the intact gp42 protein.
The gp42 N termini form packing interactions between layersStructure 17, 223of the CTLD domains in the crystal lattice (Figure 2A), wrapping
around neighboring gp42 molecules (Figure 2B). The interprotein
interactions of residues 83–94 and 76–94 appear to be important
for the gp42 lattice, and this packing arrangement may be
related to the unusual crystallization behavior in which initial
gp42 precipitation converts to crystals.
Interestingly, the immediate symmetry contacts formed by
residues 87–93 are identical in models A and B, showing super-
imposable interactions with neighboring HLA class II receptor
binding site residues (104–110) of symmetry-related gp42 mole-
cules (Figure 3). The conformations, hydrogen bond, and van
der Waals contacts of residues 87–93 in both models are–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 225
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Structure of EBV Gp42surprisingly well conserved, burying 416 A˚2 of surface area on
the extended peptide and suggesting a potential functional
significance. For example, binding of HLA receptor would
displace residues 81–93 and could thereby provide an event
important for fusion activation. This potential mechanism is
different from, but reminiscent of, one proposed for the HSV-1
functional homolog of gp42, the gD protein. The flexible C-ter-
minal tail of gD in the absence of receptor is thought to be
sequestered in a gD dimer interface and then subsequently
released upon receptor binding (Carfi et al., 2001; Fusco et al.,
2005; Krummenacher et al., 2005), releasing a region that could
trigger membrane fusion. In the gp42:HLA complex solved previ-
ously, these same residues (86–93) were observed to form an
antiparallel two-stranded b sheet generating gp42 dimers in
that crystal lattice. These observations are consistent with the
possible reorganization of the oligomeric state of gp42 upon
HLA receptor binding, from open-ended polymers of gp42,
linked by residues 87–93 docked into the HLA receptor binding
site, to more discreet dimeric assemblies mediated by 87–93
b sheet formation. We have previously shown that gp42 residues
82–94 are not important for gH/gL binding, but 5-residue dele-
Figure 2. The N Terminus of Gp42 Makes
Extended Interactions in the Crystal Lattice
Protein backbone (Ca) trace diagrams of the gp42
molecule packing the crystal lattice shown in two
orientations (A and B). The N-terminal gp42 resi-
dues are shown in blue and these connect adjacent
gp42 molecules and make interlayer connections
in the lattice (A). These inter-gp42 interactions
appear to stabilize the observed N-terminal region
conformation. The CTLD is shown in yellow-green
and forms stacked planes in this crystal form. In (B),
model A discussed in the text has a longer
N-terminal segment visible as a staple-like confor-
mation, whereas model B has a shorter L-shaped
conformation.
tions within this region block membrane
fusion activity (Kirschner et al., 2007).
Comparison of the Gp42 Structures
and Observation of gH/gL Binding
Residues
A superposition of the two gp42 mole-
cules in the asymmetric unit (Figures 4A
and 4B) shows the overall similarities.
Deviations occur primarily in the N-ter-
minal region before residue 87 and in
one loop of the CTLD (the 167 loop),
which adopts two distinct conformations.
The additional N-terminal residues
observed in one of the gp42 molecules
(model A residues 76–82) include amino
acids directly implicated in binding gH/
gL (Figure 4). Deletion mutagenesis and
peptide binding studies suggest that
the gH/gL binding site on gp42 includes
residues from 36–81, probably involving
extensive interactions throughout at least
two major segments of this region of gp42 (Kirschner et al.,
2007). Importantly, residues around the HLA binding site are in
essentially identical positions in models A and B, and these
both differ from the receptor-bound conformation.
The visualization of the gH/gL binding site residues provides
structural insight into the spatial relationships between the func-
tional regions of gp42 that have been identified as important in
EBV entry. There are three functional sites in gp42: the gH/gL
binding site, the HLA binding site, and the hydrophobic pocket
(Figure 4). Whereas the hydrophobic pocket and HLA binding
sites are structurally adjacent to one another within the CTLD,
the gH/gL binding site is located 50 A˚ away through a linker
region that spans residues 82–94. How these gp42 interaction
sites coordinate the process of membrane fusion remains to
be clarified.
Comparison to the HLA-Bound Gp42 Structure
Structural differences between the free gp42 structure and the
previously determined receptor-bound gp42:HLA-DR1 complex
may indicate the mechanism by which gp42 transmits a signal
from receptor binding to trigger membrane fusion. Alignment226 Structure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved
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Structure of EBV Gp42of the free gp42 structure with that of the gp42 receptor-bound
structure reveals three regions exhibiting significant structural
differences. These are the N-terminal region, the 167 loop, and
the 158 loop and adjacent a2 helix (Figure 4C). Only one of the
unbound gp42 models exhibits a distinct conformation for the
167 loop, whereas the other is similar to the receptor-bound
form. In addition, the 167 loop has high overall B factors, indica-
tive of its flexibility, and is distant from the HLA binding site. It is
therefore unlikely that the observed variation in conformation is
linked to receptor binding.
The gp42 N-terminal region is also not close to the HLA
binding site, but the observed packing of residues 87–93 into
the HLA binding site of a neighboring gp42 molecule raises the
possibility that this interaction could be disrupted by receptor
binding. In the unbound gp42 structure, an additional 10 N-ter-
minal residues could be observed in the electron density maps
for model A beyond what was observed in the receptor-bound
gp42 N-terminal structure (Figure 4). In both gp42 structures,
these N-terminal residues remain an outstretched chain
wandering away from the globular CTLD, and the extreme N-ter-
minal gp42 region is exposed and available for gH/gL binding.
Figure 3. Residues 87–93 Pack Identically
into Symmetry-Related HLA Binding Sites
The gp42 N-terminal residues that are immediately
proximal to the CTLD extend similarly in the two
copies of the gp42 molecules in the asymmetric
unit and make identical packing interactions with
the HLA binding site of a neighboring molecule.
(A) The overlay of the two gp42 molecules of the
asymmetric unit is shown in beige, with the N-ter-
minal residues in yellow stick representation that
form this packing interaction with the neighboring
gp42 (blue). The HLA binding site is indicated and
the corresponding residues are shown as sticks.
(B) A zoomed-in view of this packing interaction is
shown, along with the packing of residue F88
against hydrophobic HLA binding residues.
The path that the flexible N terminus
follows is different in the unbound and
receptor-bound gp42 crystal structures
(Figure 4C), clearly dependent on the
crystal packing interactions. The initial
paths of these residues projecting from
the CTLD are divergent, with the N ter-
minus in the gp42 receptor complex
taking a more oblique angle from the
CTLD. As previous studies have indi-
cated that the gH/gL binding site is con-
tained within residues 36–81, this would
leave an 5 residue linker (residues 82–
86) between residues 87–93 and gH/gL,
potentially allowing the observed oligo-
merization interactions to occur in gH/
gL/gp42 complexes at the membrane
surface.
The third region with structural differ-
ences is located within and adjacent to
the HLA binding site and the hydrophobic
pocket, with an apparently concerted shift in the gp42 a2 helix
and reorganization of the neighboring C-terminal 158 loop
(Figure 5). Overall, the hydrophobic pocket is narrower in the
unbound gp42 structure and broader in the receptor-bound
form. The rmsd determined by least-squares fit between
the main-chain atoms of the CTLD (residues 94–221) of the
receptor-bound and unbound gp42 molecules is 0.871 A˚. The
158 loop (residues 156–161) is adjacent to the gp42 a2 helix,
which contacts HLA-DR1 at its C-terminal end. This loop could
be responsible for providing a conformational signal for trig-
gering viral entry because it lines one side of the large hydro-
phobic pocket and also borders the HLA binding site.
In the unbound form of gp42, residues A158 and I159 are
shifted toward the center of the pocket reducing its diameter
(yellow, Figure 5B), whereas in the receptor-bound gp42 form,
movement of the loop and these residues broadens the internal
hydrophobic surface. Residues 155–160 are observed to shift
positions, down and to the left as shown in the figure, between
the two gp42 conformations (gray-blue, HLA-bound; yellow,
unbound). In the receptor complex, residue N155 makes biden-
tate hydrogen bonds to the backbone residues within the HLA b1Structure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 227
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Structure of EBV Gp42domain a-helical region. In addition, gp42 residues N157 and
E160 form interactions with a lysine residue (Kb65) on the
receptor, tethering these two ends of this segment to the HLA
protein. Interestingly, N157 in the unbound form adopts
a different rotamer conformation and is tucked into the loop
formed by residues A158–E160, with the amino group of the
amide side chain forming hydrogen-bond interactions with the
Figure 4. Comparison of Gp42 Structures
(A and B) The superposition of the two gp42 molecules in the asymmetric unit
is shown, rotated 90 from each other. The N-terminal residues implicated in
binding gH/gL (76–81) are indicated by pale green Ca spheres. The hydro-
phobic pocket residues and HLA binding residues are indicated as red and
cyan Ca spheres. The two gp42 molecules differ most significantly in their
extreme N-terminal regions and also in the 167 loop (indicated in purple and
blue).
(C) The free gp42 structures are shown in beige overlaid with the gp42 struc-
ture in complex with HLA-DR1 in red. Structural differences are observed in the
N-terminal region, the HLA binding site in the a2 helix, and the 158 loop, as
discussed in the text and in Figure 5.228 Structure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd Abackbone atoms, potentially buttressing this loop (Figure 5B).
Leucine 156 acts as a ‘‘slippery’’ anchor for the 158 loop, ap-
pearing to enable a change in position by sliding and reorienting
against the protein’s hydrophobic core. The overall shift of A158
and I159 (2 A˚) may open the hydrophobic pocket to enable
a large protein ligand to bind during fusion.
A third loop that moves its position in the two structures is on
the opposite side of the gp42 hydrophobic pocket, spanning
residues 187–191. The main-chain and side-chain orientations
for those residues are also significantly shifted between the
receptor-bound and free gp42 structures (Figure 5), but these
changes do not appear to be linked in a direct fashion to HLA
binding. Overall, the comparison of the two structures reinforces
the idea that there is plasticity in the gp42 hydrophobic pocket
and that the shape, dynamics, and interactions of the pocket
may be influenced directly by HLA binding.
Effects of Mutations in the Proximal N-Terminal
and 158 Loop Regions
Residues 87–93 in the N-terminal region of gp42 adopt two
distinct conformations in the free and HLA-bound gp42 crystal
structures. In the unbound crystal structure, this segment inter-
acts with the HLA binding site of a neighboring gp42 molecule
and could be displaced by HLA binding to initiate membrane
fusion. In the HLA-bound crystal structure, the same residues
form an intermolecular dimerization interface. In both crystal
structures, residue F88 forms interactions with other hydrophobic
residues (Figure 3; Mullen et al., 2002) that appear significant.
In order to test whether residue F88 is important for gp42-
mediated fusion, this residue was mutated to alanine, glutamic
acid, and lysine and the mutants were first analyzed for expres-
sion, secretion, and binding to HLA class II. All of the mutants
were expressed, secreted, and bound to HLA class II similarly
to wild-type gp42 (data not shown). Next, the mutants were
analyzed in cell:cell fusion assays (Figure 6). The F88A and
F88K mutants were active at close to 50% of wild-type fusion,
and F88E was close to 40% activity. These data suggest that
side-chain-specific interactions at residue 88 are not absolutely
required for gp42-mediated fusion, although there is a modest
decrease in fusion activity.
Mutations were also made in the 158 loop and gp42 a2 a helix
to probe the role of this loop in fusion activation. Larger hydro-
phobic amino acids were introduced into position 158, changing
the alanine to either phenylalanine or methionine. A mutation at
residue N155 to glutamic acid was made to test the role of the
bidentate hydrogen bond formed with the HLA molecule
(Figure 5), and a deletion of residues 156 and 157 (D156-157)
was made to test whether the 158 loop could be repositioned
by deletion to generate an open hydrophobic pocket and hyper-
fusogenic phenotype. All mutants were expressed and secreted
similarly to wild-type gp42 (data not shown). Mutants of amino
acid 158 bound HLA class II comparable to wild-type gp42,
whereas the N155E mutant did not bind class II over background
and the D156-157 mutant bound at approximately 35% of the
level observed with wild-type gp42 (data not shown). Mutations
of residue 158 yielded fusion activities that were not significantly
different from wild-type fusion activity (Figure 6). However, the
mutation of N155 to glutamic acid yielded an inactive gp42 in
fusion (Figure 6). The N155E mutation would allow one of thell rights reserved
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methylene group and introduces a negative charge at neutral pH,
which may account for the loss in HLA binding and fusion
activity. Finally, deletion of residues 156-157 did not yield
enhanced fusion, but reduced fusion to30% of wild-type levels
(Figure 6), comparable to the level of HLA class II binding
observed (data not shown). These results are consistent with
the roles of these residues in HLA binding and the importance
of the 158 loop in the process of fusion activation, but do not
provide definitive evidence for or against the importance of the
observed structural changes.
Structural Implications for Gp42 Function
The N-terminal region of gp42 is a flexible extended chain of resi-
dues in both the free and receptor-bound gp42 structures which
adopts crystal-specific conformations. This region also contains
the binding site residues for gH/gL, and the observed conforma-
tional diversity in the crystal structures is consistent with the func-
tional experiments showing that synthetic peptides bind to gH/gL
Figure 5. Comparison of Conformational
Changes in the Free and HLA-Bound Gp42
Structures
The structures of native (yellow) and HLA-bound
(gray-blue) gp42; residues 94–220 (lectin domains)
are superimposed. HLA class II is shown in dark
blue.
(A) Ribbon diagram of the comparison, showing
conformational changes in the HLA binding site
as well as in surface loops surrounding the hydro-
phobic pocket. Mutant sites (residues 193, 206,
and 210) that disrupt membrane fusion but not
HLA binding are also indicated by red spheres
(Ca atoms). A concerted shift in the gp42 a2 helix
and the C-terminal ‘‘158 loop’’ is observed, as well
as changes in loops across the hydrophobic
pocket. Overall, the changes result in a broader
opening of the hydrophobic pocket residues
above the helix.
(B) Details of the residue interactions that accom-
pany the conformational change in the a2 helix
and the 158 loop. In the native, unbound form
(yellow), residues 157–160 are shifted higher
above the HLA binding interface. In the HLA-
bound conformation (gray-blue), residues 155
and 156 shift to the left (bold arrow), the 158 loop
shifts down (bold arrow), and residue 157 swings
out of a set of interactions with the loop backbone
to engage HLA residue Kb65. This shift may be
triggered by hydrogen bonds formed by N155 to
the HLA b1 domain helix and through interactions
of residues 157 and 160 with Kb65. Oxygen atoms
are shown in red and nitrogen atoms are in blue.
with similar affinity as intact gp42.
Specific interactions are made between
N-terminal residues and the HLA binding
site of another gp42 molecule in the
unbound gp42 crystal structure (Fig-
ure 3A). Furthermore, the N-terminal
gp42 residues project outward from the
CTLD in a different path from that seen
in the HLA receptor-bound gp42 structure, suggesting N-terminal
changes could occur as the protein adopts a different conforma-
tion when it binds its receptor (Figure 4C). Residues 82–94, which
contain the crystal packing interaction observed here, are not
important for gH/gL binding but are important for membrane
fusion activity, as deletions within this region abrogate fusion
(Kirschner et al., 2007). The F88A, F88E, and F88K mutants
generated here retain a significant amount of the wild-type fusion
activity, which suggests the side chain of residue F88 does not
play a sequence-specific role in membrane fusion (Figure 6).
Taken together, these observations do suggest that the gp42
N-terminal residues between the gH/gL binding site and the
CTLD may play an important role in maintaining the efficiency of
membrane fusion, perhaps providing a flexible linker between
the gH/gL and HLA binding sites that allows reorientation of the
CTLD during fusion activation. However, the precise role of this
region is incompletely understood.
Comparison of the free gp42 and the receptor-bound gp42
models reveals that binding of HLA-DR1 causes a shift in theStructure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 229
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Structure of EBV Gp42Figure 6. Gp42 Mutants in Cell:Cell Fusion
The A158F, A158M, F88A, F88E, F88K, N155E,
and D156-157 mutants were expressed, secreted,
and bound to HLA class II similarly to wild-type,
except N155E did not bind HLA class II and
D156-157 bound HLA class II at approximately
35% of wild-type gp42 (data not shown). Muta-
tions of residue F88 to alanine, glutamic acid, or
lysine gave intermediate fusion activity at 40%–
50% of wild-type. Mutations at residue 158 had
minimal effects on fusion activity, whereas muta-
tion N155E or D156-157 reduced HLA binding
and fusion. Data shown are the averages of at
least five independent experiments with wild-
type gp42 luciferase activity set at 100%, and
standard deviations are represented by the error
bars.main chain of two loops and the a2 helix at the boundary of the
hydrophobic pocket (Figure 7). Although it is possible that the
structural differences are due to crystal packing interactions,
the proximity of the 158 loop to the HLA receptor and the
concerted shifts and conformational changes in the HLA binding
residues suggest a structural coupling between the loop con-
formation and HLA binding. Relatively small conformational
changes in proteins, potentially coupled to changes in protein
dynamics in some cases, have been observed to have significant
biological effects. Well-known examples include the oxy-deoxy
transition in hemoglobin (Schumacher et al., 1995), and speci-
ficity of T cell receptor recognition of MHC:peptide complexes
(Wucherpfennig et al., 2007).230 Structure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd AllThe triggering of viral membrane fusion through binding of
a receptor is similarly performed by other herpesviruses. The
HSV-1 gD protein acts as a functional homolog to EBV gp42 in
that gD binds to its receptor, HVEM, and undergoes a conforma-
tional change that allows recruitment of gH/gL and subsequently
gB, to complete the membrane fusion process (Subramanian and
Geraghty, 2007). Although the changes in the gp42 158 loop and
hydrophobic pocket are relatively small, they are likely functionally
significant because they are coupled to binding to the HLA
receptor and allow gp42 to perform its role in triggeringmembrane
fusion with B cells through the other glycoproteins, gH/gL and gB.
Although it remains to be established precisely what role the
gp42 hydrophobic pocket plays in membrane fusion, it is knownFigure 7. Model for Gp42-Dependent Entry
of EBV into B Cells
The N-terminal region of gp42 (N-term) binds pre-
fusion gH/gL (pink ovals) with high affinity on the
virus surface. The gp42 C-terminal lectin domain
(beige ribbon) binds to the HLA class II protein
(light orange ribbon). Structural data from the
native unbound gp42 form show the initial posi-
tions of the 158 loop (158), hydrophobic pocket
(HP), and N terminus. Structural data from the
receptor-bound form of gp42 demonstrate that
after receptor binding the ‘‘158 loop’’ shifts toward
the HLA molecule (curved arrow), while the hydro-
phobic pocket widens (double-headed arrow).
Membrane fusion requires the gB protein (green),
whose prefusion conformation has yet to be deter-
mined (green oval). Changes in the conformation
of the gp42 hydrophobic pocket may trigger
changes in gH/gL or gB to initiate fusion. The
conformation of gB after membrane fusion is
modeled using the crystal structure of the HSV-1
gB protein. It is not known whether gH/gL
undergoes a conformational change during fusion,
but a potentially different postfusion state of gH/gL
is represented with an expanded, fuzzy border to
indicate this possibility and gp42 is omitted for
clarity.rights reserved
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Structure of EBV Gp42that mutating or inserting residues within it can disrupt the func-
tion of gp42 in activating membrane fusion with B cells (Silva
et al., 2004). Thus, it follows that the function of gp42 as a trigger
for membrane fusion is at least in part mediated through residues
within the hydrophobic pocket, which appears to be influenced
by binding of receptor HLA class II, based on the comparison
of the available gp42 structures (Figure 7). Broadening of the
hydrophobic pocket may modulate interactions or permit access
to a binding partner, such as gH/gL or gB, to transmit the trigger
signal for membrane fusion. Exactly how gH/gL or gB may be
affected by changes in the hydrophobic pocket needs to be es-
tablished, but it is possible that the N-terminal residues act as
a high-affinity gH/gL binding site, while the hydrophobic pocket
has weaker transient binding interactions during the process of
membrane fusion. The full structure of the N-terminal gp42
binding interactions with gH/gL must await a gH/gL crystal struc-
ture and its complexes with gp42 or gp42-derived peptides.
EXPERIMENTAL PROCEDURES
Cells and Antibodies
High Five and Sf9 insect cells, mammalian Daudi B lymphocytes, and mamma-
lian Chinese hamster ovary cells (CHO-K1) were grown and used as previously
described (Kirschner et al., 2006, 2007). Polyclonal anti-gp42 antibody serum
was used as previously described (McShane et al., 2003; Silva et al., 2004).
Protein Expression, Purification, and Modification
Expression of soluble gp42 was performed as previously described (Mullen
et al., 2002). Purification of soluble gp42 was performed as previously
described (Kirschner et al., 2006). Purified gp42 protein was concentrated to
1 mg/ml and treated with 5–10 U recombinant enterokinase (EMD Biosci-
ences) per 0.5 mg protein at room temperature for 16 hr. The enzyme was
inactivated by addition of 1 mM PMSF and removed from the solution by
EKapture agarose (EMD Biosciences). Next, to protect the free cysteine
114 without prior reduction or denaturation to leave native disulfide bonds
unaffected (Aitken and Learmonth, 2003), 100 mM Tris (pH 8) and 50 mM
iodoacetamide were added to the gp42 solution and incubated on ice for
30 min. Adding 50 mM L-cysteine for 10 min quenched the reaction. The
protein solution was concentrated in a Vivaspin 2 hydrosart 10 kDa molecular
mass cutoff concentrator (Sartorius). Final purification was achieved by gel
filtration. Some gp42 stocks were further modified by reductive alkylation,
using methanol-free 16% formaldehyde (Polysciences) and borane dimethyl-
amine complex (Sigma). Methylation of lysine side chains and N-terminal
amines was performed as a possible method for improving crystallization
and diffraction (Rayment, 1997; Schubot and Waugh, 2004).
Crystallization
Gel-filtration purified, enterokinase-cut, and iodoacetamide-modified soluble
gp42 protein was concentrated to 10 mg/ml, as measured by absorbance
at 280 nm using a theoretical absorbance 0.1% of 2.36 with an
ND-1000 spectrophotometer (Nanodrop Technologies). In hanging-drop
screens using Linbro plates with 0.5 + 0.5 ml drops, Wizard I random sparse
matrix crystallization screen condition 41 (Emerald BioSystems) (30% PEG-
3000 [w/v], 100 mM CHES [pH 9.5]) initially caused heavy precipitation, but
after 3–7 days produced amorphous-shaped crystals that diffracted poorly.
The crystal appearance and number was improved by addition of 2 ml of deion-
ized water to the drop setup with 1 ml of protein and 1 ml of precipitant solution
containing the additive 10 mM YCl3. The crystals grew out of initial heavy
precipitate as small, thin square-shaped plates with sharp well-defined edges.
Fresh PEG solutions were required to reproducibly generate crystals, which
grew in CHES buffer at pH 9.5, 10, and 10.5, but not at pH 9.0.
The data presented here were collected from a single crystal grown in a drop
initially containing 1 ml of 27% PEG-3000, 90 mM CHES (pH 9.5), 10 mM YCl3;
1 ml of gp42 (reductively methylated) at 10 mg/ml in 25 mM Tris (pH 7.4),
150 mM NaCl; and 2 ml deionized water. The drop was streak seeded at setupStructure 17, 223using a cat whisker drawn across another drop containing small crystals. The
drop was equilibrated over a well containing 0.95 ml of 27% PEG-3000, 90 mM
CHES (pH 9.5). Crystals formed 6 days after setup and grew to a maximum size
of 100 3 100 3 20 mm3 up to 2 months after setup. The typical harvesting
protocol involved increasing the drop size by adding 10 ml of 30% PEG-
3000, 100 mM CHES (pH 9.5), 25 mM Tris (pH 7.5), 150 mM NaCl, 10 mM
YCl3, before moving crystals from the drop into cryoprotective solutions.
Cryoprotection
The crystals were robust to handling and transfers with premounted nylon
cryoloops (Hampton Research). They were transferred to cryobuffer solution
containing 33% PEG-3000, 100 mM CHES (pH 9.5), 25 mM Tris (pH 7.5),
150 mM NaCl, 10 mM YCl3, 15% propylene glycol, and then flash-frozen in
liquid nitrogen. Crystals frozen in this solution produced diffraction patterns
indicative of high anisotropy and disorder. Instead, the crystals were directly
moved from the drop to the final solution for freezing in a series of lower
PEG-3000 percentage solutions with a trend toward superior diffraction noted
until optimal diffraction was achieved at 10%–12% PEG-3000, which signifi-
cantly improved the diffraction anisotropy along the edge of the crystal and
increased the resolution to better than 2 A˚. The data presented here were
from a crystal initially harvested by diluting the drop with 10 ml of a solution
containing 30% PEG-3000, 100 mM CHES (pH 9.5), 10 mM YCl3, 25 mM Tris
(pH 7.5), 150 mM NaCl, and then flash-frozen in liquid nitrogen after soaking
for approximately 5 min in a solution containing 12% PEG-3000, 100 mM
CHES (pH 9.5), 10 mM YCl3, 25 mM Tris (pH 7.5), 150 mM NaCl, and 5%
propylene glycol.
Data Collection
Screening of gp42 crystals was performed at the Advanced Photon Source
(APS) at the Life Sciences Collaborative Access Team (LS-CAT) 21-ID and
Dupont-Northwestern-Dow Collaborative Access Team (DND-CAT) 5-ID
beamlines. The final diffraction data were collected at the APS at the Southeast
Regional Collaborative Access Team (SER-CAT) 22-ID beamline using a single
crystal approximately 1003 1003 20 mm3 in dimension. The X-ray wavelength
was 0.72505 A˚, which is near the K edge for yttrium. A Marccd 300 detector
was used for data collection at a distance of 400 mm, providing diffraction
to a dmin of 2 A˚ at the edge of the detector. Oscillations of 0.5
 were used to
collect 470 images with 5 s per frame.
Data Processing
All frames were used to the available limit of 2 A˚ resolution (99.1% complete) to
build and refine the initial gp42 protein model. Radiation damage to the crystal
caused a decrease in resolution and, based on the Rmerge statistics per frame,
the data set was subsequently truncated to 2.4 A˚ as a reasonable resolution
limit for the final model. HKL2000 containing the Denzo and Scalepack
programs was used for indexing, integration, and scaling. The Bravais lattice
was assigned to primitive orthorhombic with cell dimensions a = 64.79,
b = 67.43, and c = 79.46 A˚. The CCP4 program Phaser was used for molecular
replacement using the model of HLA-bound gp42 (Protein Data Bank ID code
1KG0, chain C) to search for two gp42 molecules, based on the predicted
Matthews coefficient (Vm) of 2.1 (approximately 45% solvent content)
(CCP4, 1994; Kantardjieff and Rupp, 2003; Matthews, 1968; McCoy et al.,
2005; Murshudov et al., 1997; Read, 2001; Schwarzenbacher et al., 2004;
Storoni et al., 2004). Space group P212121 was selected to have the highest
Z score and best packing arrangement. Screw axes were confirmed by exam-
ining the output from Scalepack and the systematic absences along h, k, and l
directions in the diffraction pattern using hklview software.
Structure Refinement
Starting from the molecular replacement solution, one round of rigid-body
refinement followed by several of restrained refinement with noncrystallo-
graphic symmetry restraints between secondary structure elements were
used to improve the model. DM was used for noncrystallographic symmetry
averaging with density modification (histogram matching and solvent flat-
tening) in resolution shell steps. CCP4 Refmac version 5 and CNS version 1.2
were used to improve the model by rigid-body, bulk-solvent, and restrained
least-squares refinement (Brunger et al., 1998; Cowtan and Main, 1993). Simu-
lated annealing composite omit maps were generated in CNS and used to–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 231
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Structure of EBV Gp42guide model building. Coot was used for visualization, to add solvent mole-
cules, and to make changes to the model at each step (Emsley and Cowtan,
2004). Electron density for some N-linked glycosylation was observed at
N93, N98, and N173, but was not sufficient to model N-acetyl glucosamine
moieties. Electron density for an acetamide attached to the free C114 side
chain could also be seen at low electron density contour levels, but was not
sufficient to model. Methylation on lysines could not be observed, and therefore
no methyl groups were modeled. Procheck statistics for the final protein model
are listed in Table 1. Whatcheck was used to validate the structure before depo-
sition in the Protein Data Bank.
Mutants
Mutants were generated using a previously described double-arm PCR
protocol (Kirschner et al., 2007). Mutations were verified by sequencing.
Western Blotting, Transfection, and Fusion Assay
Western blotting and transfection of CHO-K1 cells followed by overlay with
Daudi B cells for the fusion assays were done as previously described (Kirsch-
ner et al., 2007; Silva et al., 2004).
Binding of Soluble Gp42 to HLA Class II-Expressing
Cells by Flow Cytometry
This assay was done essentially as previously described (McShane et al.,
2003; Silva et al., 2004) with modification. In the current assay, only antibodies
to gp42 were used to follow gp42 binding, in contrast to the earlier studies in
which antibodies directed against HLA class II were also used to monitor HLA
class II expression.
ACKNOWLEDGMENTS
The authors would like to thank Beth Wurzburg, Jacob P. Keller, Marija Back-
ovic, and other members of the Jardetzky and Longnecker laboratories for
helpful discussions. The authors thank Jaime Schneider for assistance with
protein handling and initial crystallization trials. The authors thank Zdzislaw
Warwzak for assistance at beamlines 5-ID (Dupont-Northwestern-Dow
Collaborative Access Team) and 21-ID (Life Sciences Collaborative Access
Team) of the Advanced Photon Source, which were used to collect X-ray
data for screening gp42 crystals. Data published in this manuscript were
collected at beamline 22-ID (Southeast Regional Collaborative Access
Team), with appreciation for assistance by Gregory Sahli. A.N.K. was sup-
ported in part by a predoctoral fellowship from Northwestern’s Biotechnology
Training Program from the National Institutes of Health and by Northwestern’s
Medical Scientist Training Program (5 T32 GM008152). J.S. was supported by
the Training Program in Viral Replication (NIH T32 AI060523). This work was
supported by Public Health Service grants CA93444 and CA117794 from the
National Cancer Institute (T.S.J. and R.L.).
Received: September 15, 2008
Revised: November 24, 2008
Accepted: December 10, 2008
Published: February 12, 2009
REFERENCES
Aitken, A., and Learmonth, M. (2003). Quantitation and location of disulfide
bonds in proteins. Methods Mol. Biol. 211, 399–410.
Borza, C.M., and Hutt-Fletcher, L.M. (2002). Alternate replication in B cells and
epithelial cells switches tropism of Epstein-Barr virus. Nat. Med. 8, 594–599.
Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-
Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al.
(1998). Crystallography & NMR system: a new software suite for macromolec-
ular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54, 905–921.
Carfi, A., Willis, S.H., Whitbeck, J.C., Krummenacher, C., Cohen, G.H., Eisen-
berg, R.J., and Wiley, D.C. (2001). Herpes simplex virus glycoprotein D bound
to the human receptor HveA. Mol. Cell 8, 169–179.232 Structure 17, 223–233, February 13, 2009 ª2009 Elsevier Ltd AlCCP4 (Collaborative Computational Project, Number 4). (1994). The CCP4
suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystal-
logr. 50, 760–763.
Cowtan, K.D., and Main, P. (1993). Improvement of macromolecular electron-
density maps by the simultaneous application of real and reciprocal space
constraints. Acta Crystallogr. D Biol. Crystallogr. 49, 148–157.
Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for molecular
graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132.
Fusco, D., Forghieri, C., and Campadelli-Fiume, G. (2005). The pro-fusion
domain of herpes simplex virus glycoprotein D (gD) interacts with the gD
N terminus and is displaced by soluble forms of viral receptors. Proc. Natl.
Acad. Sci. USA 102, 9323–9328.
Haan, K.M., Lee, S.K., and Longnecker, R. (2001). Different functional domains
in the cytoplasmic tail of glycoprotein B are involved in Epstein-Barr virus-
induced membrane fusion. Virology 290, 106–114.
Heldwein, E.E., Lou, H., Bender, F.C., Cohen, G.H., Eisenberg, R.J., and
Harrison, S.C. (2006). Crystal structure of glycoprotein B from herpes simplex
virus 1. Science 313, 217–220.
Kantardjieff, K.A., and Rupp, B. (2003). Matthews coefficient probabilities:
improved estimates for unit cell contents of proteins, DNA, and protein-nucleic
acid complex crystals. Protein Sci. 12, 1865–1871.
Kirschner, A.N., Omerovic, J., Popov, B., Longnecker, R., and Jardetzky, T.S.
(2006). Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1
stable complex that acts like soluble gp42 in B cell fusion but not in epithelial
cell fusion. J. Virol. 80, 9444–9454.
Kirschner, A.N., Lowrey, A.S., Longnecker, R., and Jardetzky, T.S. (2007).
Binding site interactions between Epstein-Barr virus fusion proteins gp42
and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane
fusion. J. Virol. 81, 9216–9229.
Krummenacher, C., Supekar, V.M., Whitbeck, J.C., Lazear, E., Connolly, S.A.,
Eisenberg, R.J., Cohen, G.H., Wiley, D.C., and Carfi, A. (2005). Structure of
unliganded HSV gD reveals a mechanism for receptor-mediated activation
of virus entry. EMBO J. 24, 4144–4153.
Lazear, E., Carfi, A., Whitbeck, J.C., Cairns, T.M., Krummenacher, C., Cohen,
G.H., and Eisenberg, R.J. (2008). Engineered disulfide bonds in herpes
simplex virus type 1 gD separate receptor binding from fusion initiation and
viral entry. J. Virol. 82, 700–709.
Li, Q., Turk, S.M., and Hutt-Fletcher, L.M. (1995). The Epstein-Barr virus (EBV)
BZLF2 gene product associates with the gH and gL homologs of EBV and
carries an epitope critical to infection of B cells but not of epithelial cells.
J. Virol. 69, 3987–3994.
Matthews, B.W. (1968). Solvent content of protein crystals. J. Mol. Biol. 33,
491–497.
McCoy, A.J., Grosse-Kunstleve, R.W., Storoni, L.C., and Read, R.J. (2005).
Likelihood-enhanced fast translation functions. Acta Crystallogr. D Biol. Crys-
tallogr. 61, 458–464.
McShane, M.P., and Longnecker, R. (2004). Cell-surface expression of
a mutated Epstein-Barr virus glycoprotein B allows fusion independent of
other viral proteins. Proc. Natl. Acad. Sci. USA 101, 17474–17479.
McShane, M.P., Mullen, M.M., Haan, K.M., Jardetzky, T.S., and Longnecker,
R. (2003). Mutational analysis of the HLA class II interaction with Epstein-
Barr virus glycoprotein 42. J. Virol. 77, 7655–7662.
Mullen, M.M., Haan, K.M., Longnecker, R., and Jardetzky, T.S. (2002). Struc-
ture of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor
HLA-DR1. Mol. Cell 9, 375–385.
Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macro-
molecular structures by the maximum-likelihood method. Acta Crystallogr. D
Biol. Crystallogr. 53, 240–255.
Omerovic, J., Lev, L., and Longnecker, R. (2005). The amino terminus of
Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and
B cells. J. Virol. 79, 12408–12415.
Rayment, I. (1997). Reductive alkylation of lysine residues to alter crystalliza-
tion properties of proteins. Methods Enzymol. 276, 171–179.l rights reserved
Structure
Structure of EBV Gp42Read, R.J. (2001). Pushing the boundaries of molecular replacement with
maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 57, 1373–1382.
Ressing, M.E., van Leeuwen, D., Verreck, F.A., Keating, S., Gomez, R.,
Franken, K.L., Ottenhoff, T.H., Spriggs, M., Schumacher, T.N., Hutt-Fletcher,
L.M., et al. (2005). Epstein-Barr virus gp42 is posttranslationally modified to
produce soluble gp42 that mediates HLA class II immune evasion. J. Virol.
79, 841–852.
Rickinson, A., and Kieff, E. (2007). Epstein-Barr virus. In Fields Virology,
D. Knipe, P. Howley, D. Griffin, R. Lamb, M. Martin, B. Roizman, and S. Straus,
eds. (Philadelphia: Lippincott, Williams and Wilkins), pp. 2655–2700.
Schubot, F.D., and Waugh, D.S. (2004). A pivotal role for reductive methylation
in the de novo crystallization of a ternary complex composed of Yersinia pestis
virulence factors YopN, SycN and YscB. Acta Crystallogr. D Biol. Crystallogr.
60, 1981–1986.
Schumacher, M.A., Dixon, M.M., Kluger, R., Jones, R.T., and Brennan, R.G.
(1995). Allosteric transition intermediates modelled by crosslinked haemoglo-
bins. Nature 375, 84–87.Structure 17, 223Schwarzenbacher, R., Godzik, A., Grzechnik, S.K., and Jaroszewski, L. (2004).
The importance of alignment accuracy for molecular replacement. Acta Crys-
tallogr. D Biol. Crystallogr. 60, 1229–1236.
Silva, A.L., Omerovic, J., Jardetzky, T.S., and Longnecker, R. (2004). Muta-
tional analyses of Epstein-Barr virus glycoprotein 42 reveal functional domains
not involved in receptor binding but required for membrane fusion. J. Virol. 78,
5946–5956.
Storoni, L.C., McCoy, A.J., and Read, R.J. (2004). Likelihood-enhanced fast
rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60, 432–438.
Subramanian, R.P., and Geraghty, R.J. (2007). Herpes simplex virus type 1
mediates fusion through a hemifusion intermediate by sequential activity of
glycoproteins D, H, L, and B. Proc. Natl. Acad. Sci. USA 104, 2903–2908.
Wang, X., and Hutt-Fletcher, L.M. (1998). Epstein-Barr virus lacking glycopro-
tein gp42 can bind to B cells but is not able to infect. J. Virol. 72, 158–163.
Wucherpfennig, K.W., Allen, P.M., Celada, F., Cohen, I.R., De Boer, R., Garcia,
K.C., Goldstein, B., Greenspan, R., Hafler, D., Hodgkin, P., et al. (2007).
Polyspecificity of T cell and B cell receptor recognition. Semin. Immunol. 19,
216–224.–233, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 233
